Immunotherapy has emerged as the fifth pillar of cancer treatment alongside surgery,
radiotherapy, chemotherapy, and targeted therapy. Immune checkpoint inhibitors are the …

Opinion Statement Immunotherapy has become one of the greatest advances in medical
oncology over the last century; however, the optimal application for the treatment of breast …

Highlights•TNBCs is one of the most heterogenous form of breast cancer appear to have
elevated numbers of immune cells infiltration.•Using immune checkpoint inhibitors (ICIs) …

Immune checkpoint inhibitors (ICIs) have led to durable clinical remissions in many
metastatic cancers. However, the single-agent efficacy of ICIs in breast cancer is low …

Recent progress in immunobiology has led the way to successful host immunity
enhancement against breast cancer. In triple-negative breast cancer, the combination of …

The immune tumour microenvironment has been shown to play a crucial role in the
development and progression of cancer. Expression of gene signatures, reflecting immune …

Advances in cancer immunotherapy and a growing body of research have focused on the
role of the antitumor response in breast cancer. Triple‐negative breast cancer (TNBC) is the …

The advent of immunotherapy, particularly immune checkpoint inhibitors (ICIs), has
revolutionized the treatment of solid tumor malignancies. In breast cancer, the most robust …

The development of immunotherapy agents has revolutionized the field of oncology. The
only FDA-approved immunotherapeutic approach in breast cancer consists of immune …

More than 70% of breast cancers contain lymphocytic infiltration in the stroma, and
preclinical studies suggest that immunoediting and partial control of cancer progression by …